Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
Clinical trial NCT03983928 · UNKNOWN
Trial details
- NCT number
- NCT03983928
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-03
- Primary completion
- 2020-10-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.